{"id":48909,"date":"2024-03-09T00:37:18","date_gmt":"2024-03-08T23:37:18","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=48909"},"modified":"2024-03-08T17:00:32","modified_gmt":"2024-03-08T16:00:32","slug":"experimenty-na-lidech-pokracuji-nove-vakciny-zpusobuji-paralyzu","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2024\/03\/09\/experimenty-na-lidech-pokracuji-nove-vakciny-zpusobuji-paralyzu\/","title":{"rendered":"Experimenty na lidech pokra\u010duj\u00ed. Nov\u00e9 vakc\u00edny zp\u016fsobuj\u00ed paral\u00fdzu"},"content":{"rendered":"
<\/div>\n
\n
\n

Nov\u00e1 vakc\u00edna proti respira\u010dn\u00edmu syncyci\u00e1ln\u00edmu viru (RSV), propagovan\u00e1 jako stejn\u011b bezpe\u010dn\u00e1 jako ta proti viru Covid a narychlo schv\u00e1len\u00e1 evropsk\u00fdmi \u00fa\u0159ady, m\u00e1 pro \u201eo\u010dkovan\u00e9\u201c zni\u010duj\u00edc\u00ed n\u00e1sledky.\u00a0Americk\u00e9 centrum pro kontrolu a prevenci nemoc\u00ed (CDC) zjistilo, \u017ee tyto vakc\u00edny zp\u016fsobuj\u00ed Guillain-Barre syndrom, neurologickou poruchu charakterizovanou vzestupnou paral\u00fdzou.<\/strong><\/p>\n

Vakc\u00edny proti respira\u010dn\u00edmu syncyci\u00e1ln\u00edmu viru (RSV) schv\u00e1len\u00e9 loni Evropskou l\u00e9kovou agenturou si ji\u017e vy\u017e\u00e1daly sv\u00e9 prvn\u00ed ob\u011bti.\u00a0P\u0159edstavitel\u00e9 americk\u00e9ho Centra pro kontrolu a prevenci nemoc\u00ed (CDC) tento t\u00fdden uvedli, \u017ee zkoumaj\u00ed souvislost mezi neurologick\u00fdmi poruchami u star\u0161\u00edch Ameri\u010dan\u016f a nov\u011b schv\u00e1len\u00fdmi vakc\u00ednami, uv\u00e1d\u00ed theepochtimes.com.<\/span><\/p>\n

Vakc\u00edny proti RSV jsou podez\u0159el\u00e9 z toho, \u017ee zp\u016fsobuj\u00ed Guillain-Barre\u016fv syndrom (GBS), zn\u00e1m\u00fd tak\u00e9 jako vzestupn\u00e1 Landryho obrna.\u00a0Jde o autoimunitn\u00ed z\u00e1n\u011btliv\u00e9 onemocn\u011bn\u00ed perifern\u00edho nervov\u00e9ho syst\u00e9mu charakterizovan\u00e9 rychl\u00fdm n\u00e1stupem svalov\u00e9 slabosti a ochrnut\u00edm sval\u016f doln\u00edch a horn\u00edch kon\u010detin, d\u00fdchac\u00edch cest a obli\u010deje.<\/span><\/p>\n

V roce 2023 schv\u00e1lil americk\u00fd \u00da\u0159ad pro kontrolu potravin a l\u00e9\u010div (FDA) proti tomuto viru vakc\u00edny Abrysvo od Pfizer a Arexvy od Glaxo-Smith-Kline.\u00a0K 16. \u00fanoru \u00fa\u0159ady CDC zaznamenaly 23 p\u0159\u00edpad\u016f GBS, ke kter\u00fdm do\u0161lo b\u011bhem t\u00fddn\u016f po o\u010dkov\u00e1n\u00ed proti RSV.\u00a0Patn\u00e1ct p\u0159\u00edpad\u016f se vyskytlo u lid\u00ed o\u010dkovan\u00fdch vakc\u00ednou Pfizer RSV a osm p\u0159\u00edpad\u016f se vyskytlo u vakc\u00edny Arexvy.\u00a0\u201eSt\u00e1le jsme v ran\u00e9 f\u00e1zi zav\u00e1d\u011bn\u00ed t\u011bchto nov\u00fdch vakc\u00edn proti RSV.\u00a0N\u011bkter\u00e9 z t\u011bchto \u00fadaj\u016f a zji\u0161t\u011bn\u00ed jsou zalo\u017eeny na mal\u00e9m po\u010dtu p\u0159\u00edpad\u016f a relativn\u011b mal\u00e9m po\u010dtu podan\u00fdch d\u00e1vek.\u00a0Kv\u016fli nejistot\u00e1m a omezen\u00edm nem\u016f\u017eeme z t\u011bchto ran\u00fdch \u00fadaj\u016f usuzovat, \u017ee existuje zv\u00fd\u0161en\u00e9 riziko GBS po o\u010dkov\u00e1n\u00ed proti RSV u lid\u00ed star\u0161\u00edch 60 let,\u201c \u0159ekl Dr.\u00a0Thomas Shimabukuro, \u0159editel \u00fa\u0159adu CDC pro bezpe\u010dnost vakc\u00edn.<\/span><\/p>\n

Zrychlen\u00e9 hodnocen\u00ed<\/strong><\/span><\/p>\n

Evropsk\u00e1 l\u00e9kov\u00e1 agentura (EMA) ozn\u00e1mila, \u017ee vakc\u00edna Arexvy byla hodnocena v r\u00e1mci zrychlen\u00e9ho postupu hodnocen\u00ed, proto\u017ee prevence infekc\u00ed RSV u star\u0161\u00ed populace je pova\u017eov\u00e1na za velk\u00fd z\u00e1jem ve\u0159ejn\u00e9ho zdrav\u00ed.\u00a0\u201eStanovisko V\u00fdboru EMA pro hum\u00e1nn\u00ed l\u00e9\u010div\u00e9 p\u0159\u00edpravky (CHMP) je zalo\u017eeno na \u00fadaj\u00edch z randomizovan\u00e9, placebem kontrolovan\u00e9 studie zahrnuj\u00edc\u00ed 25 000 dosp\u011bl\u00fdch v 17 zem\u00edch.\u00a0V\u00fdsledky uk\u00e1zaly odhadovanou 83% ochranu proti LRTD zji\u0161t\u011bn\u00e9mu RSV po dobu nejm\u00e9n\u011b \u0161esti m\u011bs\u00edc\u016f.<\/span><\/p>\n

Nej\u010dast\u011bji hl\u00e1\u0161en\u00fdmi ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky byly bolest hlavy, \u00fanava, bolest sval\u016f, bolest kloub\u016f a bolest v m\u00edst\u011b vpichu.\u00a0Studie prob\u00edh\u00e1 a posoud\u00ed \u00fa\u010dinnost jedn\u00e9 d\u00e1vky Arexvy v pr\u016fb\u011bhu n\u011bkolika sez\u00f3n a pot\u0159ebu p\u0159eo\u010dkov\u00e1n\u00ed, stejn\u011b jako sledov\u00e1n\u00ed bezpe\u010dnostn\u00edho profilu,\u201c uvedla EMA v prohl\u00e1\u0161en\u00ed.<\/span><\/p>\n

Dal\u0161\u00ed sledov\u00e1n\u00ed<\/strong><\/span><\/p>\n

Stejn\u011b jako u vir\u016f Covid, p\u0159\u00edbalov\u00fd let\u00e1k k vakc\u00edn\u00e1m RSV uv\u00e1d\u00ed, \u017ee produkt podl\u00e9h\u00e1 dal\u0161\u00edmu monitorov\u00e1n\u00ed, kter\u00e9 by umo\u017enilo rychle identifikovat nov\u00e9 bezpe\u010dnostn\u00ed informace.\u00a0Sv\u011bd\u010d\u00ed o ne\u00fapln\u00fdch studi\u00edch, v\u00fdrobce nem\u00e1 k dispozici \u00fadaje o spole\u010dn\u00e9m pod\u00e1v\u00e1n\u00ed s vysokod\u00e1vkovan\u00fdmi vakc\u00ednami proti sez\u00f3nn\u00ed ch\u0159ipce nebo s adjuvans, pou\u017eit\u00ed p\u0159\u00edpravku Arexvy u t\u011bhotn\u00fdch \u017een, vylu\u010dov\u00e1n\u00ed p\u0159\u00edpravku Arexvy do lidsk\u00e9ho nebo zv\u00ed\u0159ec\u00edho ml\u00e9ka, \u00fa\u010dink\u016f p\u0159\u00edpravku Arexvy na lidskou plodnost, pop\u0159. ovliv\u0148uje schopnost \u0159\u00eddit motorov\u00e1 vozidla nebo obsluhovat stroje.<\/span><\/p>\n

\u201eEvropsk\u00e1 l\u00e9kov\u00e1 agentura (EMA) do\u010dasn\u011b pozastavila povinnost p\u0159edkl\u00e1dat v\u00fdsledky studi\u00ed proveden\u00fdch s Arexvy u jedn\u00e9 nebo v\u00edce podskupin d\u011bt\u00ed a dosp\u00edvaj\u00edc\u00edch pro prevenci infekc\u00ed doln\u00edch cest d\u00fdchac\u00edch zp\u016fsoben\u00fdch respira\u010dn\u00edm syncyci\u00e1ln\u00edm virem,\u201c pokra\u010duje prohl\u00e1\u0161en\u00ed EMA. .<\/span><\/p>\n<\/div>\n<\/div>\n

\n
\n

ZDROJ<\/a><\/span><\/h3>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nov\u00e1 vakc\u00edna proti respira\u010dn\u00edmu syncyci\u00e1ln\u00edmu viru (RSV), propagovan\u00e1 jako stejn\u011b bezpe\u010dn\u00e1 jako ta proti viru…<\/p>\n","protected":false},"author":2,"featured_media":6384,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[23,6921,651,21],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/48909"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=48909"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/48909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/6384"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=48909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=48909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=48909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}